Wisdo Health Acquisition
Total Consideration
$4.9M
TALKSPACE, INC. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$0
Book Value Per Share
$1
Free Cash Flow Per Share
$0
Cash Per Share
$0
Revenue Per Share
$1
OCF Per Share
$0
Return on Equity
6.6%
Return on Assets
5.7%
Return on Invested Capital
2.5%
Current Ratio
6.38
Quick Ratio
6.38
Asset Turnover
1.67
Days Sales Outstanding
25.61
Days Payables Outstanding
27.66
R&D / Revenue
4.2%
SBC / Revenue
3.7%
Capex / Revenue
—
Working Capital
$94M
Net Current Asset Value
$93M
Invested Capital
$117M
OCF / Net Income
1.10
FCF / Net Income
1.10
Accruals Ratio (Sloan)
-0.5%
Net Debt
$-37M
Net Debt / EBITDA
-6.20
Capex Coverage
—
Tangible Common Equity
$110M
TCE / Total Assets
81.4%
Goodwill / Total Assets
2.5%
NOPAT
$3M
Cash ROIC
7.3%
WC / Revenue
40.9%
Capex / D&A
—
Reinvestment Rate
64.4%
Total Payout Ratio
220.7%
Asset Growth vs Revenue Growth
-24.8%
Revenue 5Y CAGR
24.6%
Stock Price (FY-end)
$4
Market Cap
$630M
P/E Ratio
80.89
P/S Ratio
2.75
P/B Ratio
5.39
P/TB Ratio
5.74
P/OCF Ratio
73.86
P/FCF Ratio
73.86
Enterprise Value
$593M
EV / EBITDA
98.39
EV / Sales
2.59
EV / FCF
69.49
FCF Yield
1.4%
Shareholder Yield
1.4%
Buyback Yield
2.7%
R&D Yield
1.5%
Capex Yield
—
Graham Number
$1
Shares Variation (YoY)
-1.6%
Beta (5Y)
1.11
Cost of Equity
10.1%
52W High
$4
52W Low
$2
Trailing Return 1Y
15.2%
Trailing Return 5Y
-65.9%
F-Score (Piotroski)
6.00
Z-Score (Altman)
21.08
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Stock Price on Earnings Dates
TALKSPACE, INC. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | — | — | — | — | — | -5.20% |
| Foreign Rate Differential | — | — | — | — | — | -0.10% |
| Other Adjustments | — | — | — | — | — | — |
| SBC (Nondeductible) | — | — | — | — | — | -3.80% |
| Valuation Allowance Change | — | — | — | — | — | -16.10% |
| Effective Tax Rate | — | — | — | — | — | 6.90% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $24.0K | $47.0K | $254.0K | $218.0K | $94.0K | $574.0K |
| Income Taxes Paid (Cash) | — | — | $122.0K | $219.0K | $96.0K | $417.0K |
TALKSPACE, INC. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.